Drs Lidia Schapira and Antonio Wolff discuss the current research on DCIS and other forms of lower-risk early breast cancer, and how medical oncologists can work to create an optimal treatment plan.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963165). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals.

Resources

Questions About the BRCA1 and BRCA2 Gene Study and Breast Cancer https://www.genome.gov/10000940/brca1brca2-study-faq

Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment https://ascopubs.org/doi/10.1200/JCO.21.01674

Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474966/

Addressing Overtreatment of Screen Detected DCIS; The LORIS Trial https://www.ejcancer.com/article/S0959-8049(15)00697-8/fulltext

Feasibility of a Prospective, Randomised, Open-label, International Multicentre, Phase III, Non-inferiority Trial to Assess the Safety of Active Surveillance for Low Risk Ductal Carcinoma In Situ -- The LORD study https://www.ejcancer.com/article/S0959-8049(15)00394-9/fulltext

The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) Trial: A Phase III Randomised Controlled Clinical Trial for Low-Risk Ductal Carcinoma In Situ (DCIS) https://bmjopen.bmj.com/content/9/3/e026797.long